Operating income before deduction of amortization: Avadel Pharmaceuticals PLC (AVDL)

Risks for Avadel Pharmaceuticals (AVDL) are tied to patents and the adoption rate of Lumryz. However, the business relies on the macro-resilience of the sector, where demand remains independent of crises. The absolute EBITDA trend confirms this stability, with its latest reading standing at 8.19. Growth is supported by partnerships with specialized sleep clinics to optimize narcolepsy therapy.

Avadel Pharmaceuticals (AVDL) Operating profit EBITDA: for the period 11/23/2025 - 02/28/2026

Summary analytical data breakdowns for Avadel Pharmaceuticals plc (AVDL)

- share price and consensus valuation forecast:

Quote Chart Avadel Corp|AVDL - Price Target Chart

- company stock exchange capitalization indicators:

Market Capitalization Avadel Pharmaceuticals|AVDL - Real Price to Acquire Entire Company

- balance sheet equity data:

Net Asset Value per Share Avadel Pharmaceuticals|AVDL - Book Capitalization|Market Cap to Net Assets Ratio avadel.com|AVDL - Company Total Assets

- company total debt and liquidity indicators:

All Debt to Shareholders' Equity Ratio Avadel Pharmaceuticals|AVDL - Long-Term Debt to Equity|Current Liabilities to Capital Avadel Pharmaceuticals PLC|AVDL - Company Aggregate Debts|Debts to Book Capitalization Avadel Pharmaceuticals|AVDL - Company Long-Term Liabilities|Company Short-Term Debt Avadel Pharmaceuticals|Quick Ratio avadel.com

- earnings and market multiples details:

AVDL - Net Profit|Net Profit Forecast Avadel Pharmaceuticals|AVDL - P/E Multiple|Projected Price to Earnings Ratio avadel.com|AVDL - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avadel Pharmaceuticals|AVDL - Operating profit before deduction of amortization|Earnings per share for the trailing year Avadel Pharmaceuticals|AVDL - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months avadel.com|AVDL - Earnings growth in current year|Expected earnings per share trend next year Avadel Pharmaceuticals

Summary company analytics:AVDL (Avadel Corp)

This indicator serves as a fundamental tool for assessing the asset's operational efficiency, capturing daily earnings before interest and taxes to reflect actual cash flow. By analyzing changes in EBITDA_Co, an investor can identify hidden demand trends prior to official reports. For Avadel Pharmaceuticals (AVDL), this metric confirms the commercial viability of its proprietary sleep medications. A stable chart indicates high capitalization of unique developments within the US market.

Competitor analysis for Avadel Pharmaceuticals

ALKS (Alkermes Corp) - Profit before deduction of interest, taxes, depreciation and amortization|ATAI - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization ghres.com GHRS|MNMD (MindMed) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization COMPASS Pathways PLC (CMPS)|LBRX (LB Pharma) - Operating profit EBITDA|Operating profit before deduction of amortization Bright Minds Corp (DRUG)|Operating profit EBITDA VNDA|CYBN (cybin.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Profit before interest, taxes and amortization|Cingulate Corp - Operating profit EBITDA|SILO - Operating profit EBITDA|CPHI (chinapharmaholdings.com) - Operating profit before deduction of amortization|CMND (clearmindmedicine.com) - Profit before payment of interest, taxes and amortization|PBM (Psyence Biomedical) - Operating profit EBITDA|Operating profit EBITDA SciSparc Ltd.|Operating profit EBITDA SEEL|virpaxpharma.com - Operating profit before amortization|Operating profit EBITDA KRTX (Karuna Therapeutics)